AtheroGenics Inc. Class Action Dismissed

Shareholders filed a class action lawsuit against the company claiming it misrepresented the results of an inconclusive and limited study of its experimental drug AGI-1067. According to the Securities and Exchange Commission, plaintiffs voluntarily dismissed the actions. (Jul-15-05) [ATLANTA BUSINESS JOURNAL]

Legal Help

If you have a similar problem and would like to be contacted by a lawyer at no obligation, please fill in our form on the right to submit your complaint.

Add Your Comment on This Issue

Fields marked * are mandatory. Please read our comment guidelines before posting.


Note: Your name will be published with your comment.

*Email Address:

Your email will only be used if a response is needed.

*Your Comment:
Request Legal Help